Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

How Machine Learning Will Affect E-commerce Industry in near future

Machine learning and artificial intelligence have in one way or the other, immensely contributed to bringing e-commerce to a value of $2.3 trillion in the market. Machine learning brought a revolution in the said field by helping merchants better analyse their businesse...

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Earl...

Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study

The highlights of the results were presented in an H.C. Wainwright & Co. report. In a June 14 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Kura Oncology Inc. (KURA:NASDAQ) met the endpoint in its Phase 2 clinical trial of...

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. After U.S. markets...

Airbus, BASF, Osino Resources - where is the highest return?

Normally, investors are happy about rising share prices, because the stock market is the expression of the future and expected growth in pricing. However, what has been observed since the outbreak of the Corona Pandemic and the measures that have accompanied it has little to d...

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. In a June 22 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Targovax ASA's (TRVX:OSE) ONCOS-102, in trial ...

Why Did ImmunoGen Plummet 32%?

This biotechnology company, which focuses on the treatment of cancer, received some feedback from the FDA that upset investors on Wednesday. ImmunoGen Inc.'s (IMGN:NASDAQ) shares closed down 32.06% on the NASDAQ Wednesday after announcing the United States ...

Construction Pipeline Shows Undervalued Opportunity

This Vancouver Construction Company Continues to Trade Undervalued with a Long List of Projects in the Pipeline. A Vancouver-based general contracting company, with a list of international jobs in the pipeline, is trading for just eight cents apiece right now. From ea...

Metrics Highlight Potential at High-Grade Canadian Silver District

Greg Johnson, president and CEO of Metallic Minerals, speaks with Maurice Jackson of Proven and Probable about why he believes the company has all the "key ingredients for success" at its project in the Keno Hill Silver District. Keno Hill Ma...

Getchell Gold’s Nevada Projects Offer Serious Upside

Getchell Gold offering loads of upside at its Fondaway Canyon gold and Star Point copper-gold projects in Nevada Identifying the opportunity in an undervalued project is where that “sweet spot” of resource investing comes in - purchasing an underval...
1 2 3 4 5 6 7 8